trending Market Intelligence /marketintelligence/en/news-insights/trending/gh3cpokdhnrrcdku_d4uga2 content esgSubNav
In This List

Precipio names replacement for departing director

Case Study

Identifying PPE Suppliers During the Pandemic


Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage


COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021


Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective

Precipio names replacement for departing director

New Haven, Conn.-based specialty cancer diagnostics company Precipio Inc. said it tapped Kathleen LaPorte to replace Michael Luther on its board.

Luther had been serving on Precipio's board since June 2017 after it merged with Transgenomic. His replacement, LaPorte, has three decades of experience as an executive and venture capitalist in the life sciences sector, Precipio said in a statement.

LaPorte served as general partner with Sprout Group from 1993 to 2004 and was one of the founders of New Leaf Venture Partners. She is a co-founder of Health Tech Capital, a group of healthcare technology focused private and corporate investors.

She is also the former chief business officer and CEO of Nodality Inc., an immuno-oncology diagnostics company.